KR102609396B1 - Ldha의 발현을 억제하기 위한 방법 및 조성물 - Google Patents

Ldha의 발현을 억제하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102609396B1
KR102609396B1 KR1020207013207A KR20207013207A KR102609396B1 KR 102609396 B1 KR102609396 B1 KR 102609396B1 KR 1020207013207 A KR1020207013207 A KR 1020207013207A KR 20207013207 A KR20207013207 A KR 20207013207A KR 102609396 B1 KR102609396 B1 KR 102609396B1
Authority
KR
South Korea
Prior art keywords
composition
ldha
oligonucleotide
positions
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013207A
Other languages
English (en)
Korean (ko)
Other versions
KR20200078530A (ko
KR102609396B9 (ko
Inventor
밥 디. 브라운
헨릭 티. 두덱
우트사브 삭세나
나탈리 퍼셀
쳉 라이
웨이민 왕
레이첼 스톨
나임 나제프
보영 김
Original Assignee
노보 노르디스크 헬스 케어 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66101691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102609396(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 헬스 케어 악티엔게젤샤프트 filed Critical 노보 노르디스크 헬스 케어 악티엔게젤샤프트
Priority to KR1020237041035A priority Critical patent/KR20230169413A/ko
Publication of KR20200078530A publication Critical patent/KR20200078530A/ko
Application granted granted Critical
Publication of KR102609396B1 publication Critical patent/KR102609396B1/ko
Publication of KR102609396B9 publication Critical patent/KR102609396B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207013207A 2017-10-13 2018-10-12 Ldha의 발현을 억제하기 위한 방법 및 조성물 Active KR102609396B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237041035A KR20230169413A (ko) 2017-10-13 2018-10-12 Ldha의 발현을 억제하기 위한 방법 및 조성물

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762572403P 2017-10-13 2017-10-13
US201762572398P 2017-10-13 2017-10-13
US62/572,403 2017-10-13
US62/572,398 2017-10-13
US201862726950P 2018-09-04 2018-09-04
US62/726,950 2018-09-04
PCT/US2018/055735 WO2019075419A1 (en) 2017-10-13 2018-10-12 METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041035A Division KR20230169413A (ko) 2017-10-13 2018-10-12 Ldha의 발현을 억제하기 위한 방법 및 조성물

Publications (3)

Publication Number Publication Date
KR20200078530A KR20200078530A (ko) 2020-07-01
KR102609396B1 true KR102609396B1 (ko) 2023-12-01
KR102609396B9 KR102609396B9 (ko) 2025-04-10

Family

ID=66101691

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207013207A Active KR102609396B1 (ko) 2017-10-13 2018-10-12 Ldha의 발현을 억제하기 위한 방법 및 조성물
KR1020237041035A Pending KR20230169413A (ko) 2017-10-13 2018-10-12 Ldha의 발현을 억제하기 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237041035A Pending KR20230169413A (ko) 2017-10-13 2018-10-12 Ldha의 발현을 억제하기 위한 방법 및 조성물

Country Status (15)

Country Link
US (4) US11286488B2 (https=)
EP (2) EP4265261A3 (https=)
JP (2) JP7308213B2 (https=)
KR (2) KR102609396B1 (https=)
CN (3) CN118530989A (https=)
AU (1) AU2018346971B2 (https=)
CA (1) CA3078933A1 (https=)
ES (1) ES2955045T3 (https=)
HR (1) HRP20231063T1 (https=)
HU (1) HUE063026T2 (https=)
IL (1) IL273875B2 (https=)
MX (1) MX2020003836A (https=)
PL (1) PL3679141T3 (https=)
RS (1) RS64483B1 (https=)
WO (1) WO2019075419A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330670B2 (en) 2014-10-10 2022-01-06 Novo Nordisk Health Care Ag Therapeutic inhibition of lactate dehydrogenase and agents therefor
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
HRP20231063T1 (hr) 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
SI3684377T1 (sl) * 2017-10-20 2023-05-31 Dicerna Pharmaceuticals, Inc. Postopki zdravljenja okužbe s hepatitisom B
WO2019143621A1 (en) 2018-01-16 2019-07-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting aldh2 expression
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
MX2022001710A (es) 2019-08-09 2022-05-10 Univ Massachusetts Oligonucleótidos modificados químicamente dirigidos a los snp.
JP2022545118A (ja) * 2019-08-23 2022-10-25 ユニバーシティー オブ マサチューセッツ Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021067744A1 (en) * 2019-10-02 2021-04-08 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
US20250205203A1 (en) * 2020-05-18 2025-06-26 Chinook Therapeutics Canada, Inc. Substituted pyrazolyl compounds and methods of use thereof
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
EP4244356A1 (en) * 2020-11-13 2023-09-20 Dicerna Pharmaceuticals, Inc. Chemical modifications for inhibiting expression of aldh2
CA3207897A1 (en) 2021-03-19 2022-09-22 Ralf Eisenhuth Improved oligonucleotide synthesis
US20250282813A1 (en) 2021-04-09 2025-09-11 Bachem Holding Ag Pseudo solid phase protecting group and methods for the synthesis of oligonucleotides and oligonucleotide conjugates
WO2022223515A2 (en) * 2021-04-19 2022-10-27 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
US20240287512A1 (en) * 2021-05-11 2024-08-29 Dicerna Pharmaceuticals, Inc. Lipid conjugation for targeting neurons of the central nervous system
JP2024523237A (ja) 2021-06-18 2024-06-28 ホンジーン バイオテック コーポレイション 官能化されたｎ－アセチルガラクトサミンヌクレオシド
WO2023003805A1 (en) 2021-07-19 2023-01-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
JP2024532019A (ja) * 2021-08-25 2024-09-05 ノボ ノルディスク エー／エス アルファ－１アンチトリプシン発現を阻害するための組成物及び方法
JP2024532271A (ja) 2021-08-30 2024-09-05 ホンジーン バイオテック コーポレイション 官能化ｎ－アセチルガラクトサミンアナログ
AR127260A1 (es) * 2021-10-05 2024-01-03 Dicerna Pharmaceuticals Inc Composiciones y métodos para inhibir el receptor de melanocortina 2 y la expresión del citocromo p450 11b
WO2023102469A2 (en) * 2021-12-01 2023-06-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating apoc3 expression
WO2023114746A1 (en) 2021-12-15 2023-06-22 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
US20260001902A1 (en) 2022-09-19 2026-01-01 Bachem Holding Ag Improved oligonucleotide synthesis
JP2025531341A (ja) * 2022-09-19 2025-09-19 カイロンノヴァ （シャーメン） バイオファーマ カンパニー，リミテッド 炭水化物－オリゴヌクレオチド複合体、薬物組成物および治療への応用
WO2024083746A1 (en) 2022-10-17 2024-04-25 Bachem Holding Ag Method and composition for oligonucleotide synthesis
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
EP4695265A1 (en) 2023-10-16 2026-02-18 Bachem Holding AG Method and composition for oligonucleotide synthesis
TW202602463A (zh) 2024-03-22 2026-01-16 日商武田藥品工業股份有限公司 用於抑制細胞色素ｐ４５０家族７次家族ａ成員１（ｃｙｐ７ａ１）表現之組成物及方法
CN118460650B (zh) * 2024-07-10 2025-02-14 凯莱英医药集团（天津）股份有限公司 一种Nedosiran的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057932A1 (en) 2014-10-10 2016-04-14 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
WO2016100401A1 (en) 2014-12-15 2016-06-23 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US10920226B2 (en) 2002-11-14 2021-02-16 Thermo Fisher Scientific Inc. siRNA targeting LDHA
US20050014692A1 (en) 2003-01-21 2005-01-20 Newgard Christopher B. Lactate dehydrogenase as a novel target and reagent for diabetes therapy
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005222965B8 (en) 2004-03-15 2010-07-01 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
CN102037123A (zh) * 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Epas1抑制剂的组合物和用途
CA2729757A1 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
JP2012504389A (ja) 2008-09-22 2012-02-23 ダイセルナ ファーマシューティカルズ， インコーポレイテッド 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
US20100173973A1 (en) 2008-12-18 2010-07-08 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
DK2539451T3 (da) 2010-02-24 2016-04-04 Arrowhead Res Corp Sammensætninger til målrettet tilførsel af siRNA
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
JP2014518626A (ja) 2011-05-18 2014-08-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 被験者が慢性腎疾患を有する、または発症するリスクがあるかどうかを決定するための方法
EP2780454A2 (en) 2011-11-18 2014-09-24 Alnylam Pharmaceuticals, Inc. Modified rnai agents
AR090906A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y procedimientos para la administracion de oligonucleotidos
JP2018500905A (ja) 2014-12-18 2018-01-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ナノチューブを使用した核酸ポリメラーゼ立体構造変化の検出
HK1252852A1 (zh) * 2015-05-29 2019-06-06 Arrowhead Pharmaceuticals, Inc. 阻止HIF2α基因表达的组合物及方法
HRP20231063T1 (hr) 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057932A1 (en) 2014-10-10 2016-04-14 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
WO2016100401A1 (en) 2014-12-15 2016-06-23 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids

Also Published As

Publication number Publication date
JP2020536587A (ja) 2020-12-17
MX2020003836A (es) 2020-11-06
EP3679141C0 (en) 2023-06-07
KR20230169413A (ko) 2023-12-15
CA3078933A1 (en) 2019-04-18
US11661604B2 (en) 2023-05-30
US20250283091A1 (en) 2025-09-11
CN111448319A (zh) 2020-07-24
JP7674420B2 (ja) 2025-05-09
EP4265261A3 (en) 2024-01-24
CN111448319B (zh) 2024-05-17
HUE063026T2 (hu) 2023-12-28
AU2018346971B2 (en) 2025-01-09
US20200283775A1 (en) 2020-09-10
EP3679141A4 (en) 2021-06-16
CN118440940A (zh) 2024-08-06
US20210062199A1 (en) 2021-03-04
JP7308213B2 (ja) 2023-07-13
EP3679141A1 (en) 2020-07-15
PL3679141T3 (pl) 2023-10-02
EP4265261A2 (en) 2023-10-25
HRP20231063T1 (hr) 2023-12-22
US11286488B2 (en) 2022-03-29
KR20200078530A (ko) 2020-07-01
JP2023139014A (ja) 2023-10-03
WO2019075419A1 (en) 2019-04-18
EP3679141B1 (en) 2023-06-07
IL273875B2 (en) 2025-07-01
IL273875B1 (en) 2025-03-01
ES2955045T3 (es) 2023-11-28
KR102609396B9 (ko) 2025-04-10
CN118530989A (zh) 2024-08-23
RS64483B1 (sr) 2023-09-29
US20240182901A1 (en) 2024-06-06
IL273875A (en) 2020-05-31
AU2018346971A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
KR102609396B1 (ko) Ldha의 발현을 억제하기 위한 방법 및 조성물
US12564601B2 (en) Methods for treating hepatitis B infection
CN119789859A (zh) 非酒精性脂肪肝病的治疗
HK40115827A (zh) 用於抑制ldha表达的方法和组合物
HK40026540B (zh) 用於抑制ldha表达的方法和组合物
HK40026540A (en) Methods and compositions for inhibiting expression of ldha
CA3128059A1 (en) Methods and compositions for inhibiting expression of cyp27a1
RU2780021C2 (ru) Способы лечения инфекции гепатита в
WO2026050125A1 (en) Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2025073276A1 (zh) 一种iRNA组合物及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200508

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211008

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230831

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231129

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231129

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20250211

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20231129

Patent event code: PJ02021E01I

Appeal kind category: Correction

Request date: 20250211

Appeal identifier: 2025105000017

J301 Trial decision

Free format text: TRIAL NUMBER: 2025105000017; TRIAL DECISION FOR CORRECTION REQUESTED 20250211

Effective date: 20250331

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20250331

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20250211

Decision date: 20250331

Appeal identifier: 2025105000017

PG1701 Publication of correction

Publication date: 20250410